Large clinical studies in humans reveal different risk factors underlying diabetic neuropathy in type 1 and type 2 diabetes, leading to the hypothesis that different pathogenetic mechanisms underlie diabetic neuropathy in type 1 and type 2 diabetes. Mouse models of diabetic neuropathy represent important tools to understand the pathophysiological mechanisms of nerve damage in diabetes and to determine differences and similarities between type 1 and type 2 diabetes. The Feldman Laboratory has developed robust murine models for diabetic neuropathy in both type 1 and type 2 diabetes. They will assess the development of diabetic neuropathy over time in murine diabetes models and correlate behavioural and physiological assessments with metabolic dysfunction and nerve hypoxia to ascertain the fundamental mechanisms underlying the two different types of diabetic neuropathy. We will employ our published protocols for behavioural, physiological, and metabolic assessments, which are now used by the NIH as the standard of practice for research protocols in diabetic neuropathy and are detailed on the NIH Diabetic Complications Consortium website (www.diacomp.org).